| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy | PDUFA | — | Antibody-Drug Conjugates (ADCs) | Oncology | ||
PDUFA Date example | KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy | PDUFA | — | Antibody-Drug Conjugates (ADCs) | Oncology | ||
PDUFA Date example | KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy | PDUFA | — | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Merck & Company, Inc.$113.87
-1.57 (-1.36%)
A 93Pipeline Score Fair Value Pharma · Commercial
Market Cap
302.33 B
EPS
3.56
P/E Ratio
34.45 $
Value Trade
947.57 M
SEC Financials
Q1 2026Dilution Risk
Revenue
16.29 B
R&D Expenses
12.59 B
Operating CF
3.92 B
Total Assets
128.69 B
Total Liabilities
128.69 B
Equity
45.88 B
D/E Ratio
12,345
7.47 %
Week
8.71 %
1 Month
-0.19 %
3 Month
28.2 %
6 Month
60.61 %
5 Year
8,098.03 %
All Time
Cash Data
Cash Position
5.70 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 4, 2026
Overview
Volume
29.52 M
52 Week Range
75.40 - 125.14
% held by Insiders
0.18 %
% held by Institutions
81.01 %
Enterprise Value
345.73 B
Total Shares
2.48 B
Short %
1.25 %
Float Shares
2.44 B
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
A93
Pipeline Score $178.5B
Pipeline ValueFair Value
Valuation Signal626
Drugs Scored2.0x
rNPV / MCap Top 100%
Large Pharma (rank 1 of 905)
Percentile RankMerck & Company, Inc. earns an A-grade pipeline score (93/100), with $178.5B risk-adjusted pipeline value, led by sitagliptin metformin in Type 2 Diabetes Mellitus (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| sitagliptin q.d./metformin ≥ /day Small molecule | Type 2 Diabetes Mellitus (T2DM) | Phase 3 | NCT00337610 | 53% | $13.6B | COMPLETED | 190 | - | - | Aug 1, 2007 | - | May 12, 2016 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
KEYTRUDA | resectable locally advanced head and neck squamous cell carcinoma | Phase 3 | 2025-06-16 | |||
KEYTRUDA | resectable locally advanced head and neck squamous cell carcinoma | Phase 3 | 2025-06-16 | |||
KEYTRUDA | resectable locally advanced head and neck squamous cell carcinoma | Phase 3 | 2025-06-16 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MRK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
MRK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MRK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MRK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MRK Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MRK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-24 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-24 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-24 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MRKCystic Fibrosis: Merck Manuals Shares What Patients and Parents Need to Know
Merck Manuals has released an editorial by Dr. Gregory Sawicki on cystic fibrosis, highlighting its genetic nature and the importance of screening for carriers and newborns. While there is no cure, recent advancements in treatments, particularly CFTR modulators, have improved patient outcomes. The article emphasizes the need for multidisciplinary care in managing the disease.
Read more →MRKStudy Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
A recent study highlights the difficulties faced by dog owners and veterinarians in managing allergic skin disease in dogs. The findings emphasize the necessity for a rapid onset treatment suitable for dogs of all ages, indicating a gap in the current treatment landscape. This underscores the urgency for advancements in veterinary dermatological therapies.
Read more →MRKJetstream Venture Fund Secures Position in Rejuvenate Bio, Investing Alongside Industry Giant Merck
Jetstream Venture Fund has announced its investment in Rejuvenate Bio, aligning with major players like Merck Animal Health. This move aims to democratize access to venture capital for retail investors. Rejuvenate Bio focuses on innovative gene therapies for chronic conditions, showcasing a promising pipeline that includes treatments for heart failure and metabolic diseases.
Read more →MRKProtillion Biosciences Announces Drug Discovery Collaboration with Merck
Protillion Biosciences has announced a collaboration with Merck focused on drug discovery. This partnership aims to leverage Protillion's technology to enhance the drug development process. Further details about the specific goals and expected outcomes of the collaboration have not been disclosed.
Read more →MRKLifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health
Rejuvenate Bio has successfully closed a $6 million financing round and announced a strategic R&D collaboration with Merck Animal Health. The funds will advance their gene therapy programs targeting chronic and age-related diseases in companion animals. This partnership highlights confidence in Rejuvenate Bio's innovative approach to improving healthspan in both animals and humans.
Read more →MRKMerck Animal Health to Acquire TARGAN
Merck Animal Health has announced its intention to acquire TARGAN. This acquisition aims to enhance Merck's portfolio in the animal health sector. Further details regarding the transaction and its implications have not been disclosed.
Read more →MRKRejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health
Rejuvenate Bio has announced a $6 million financing round alongside a strategic R&D collaboration with Merck Animal Health. This partnership aims to enhance research and development efforts in the field of animal health. The collaboration signifies a positive step towards innovation and growth for both companies.
Read more →MRKMerck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Merck and Gilead have provided an update on the Phase 3 KEYNOTE-D46/EVOKE-03 study. However, the article lacks specific details regarding the findings or implications of this update. Further information may be necessary to understand the impact of this study on the biopharma landscape.
Read more →MRKFDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
The FDA has granted Breakthrough Therapy Designation to Calderasib (MK-1084), an investigational KRAS G12C inhibitor. This designation is specifically for patients with newly diagnosed metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC). This status aims to expedite the development and review of Calderasib, highlighting its potential benefits for patients.
Read more →MRKMerck to Participate in the Jefferies Global Healthcare Conference 2026
Merck announced that Dr. Marjorie Green will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. This event will allow investors, analysts, and the public to listen to a live audio webcast of the presentation. Merck emphasizes its dedication to innovative health solutions and responsible operations.
Read more →MRKMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
Merck has received a favorable opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding the use of KEYTRUDA in combination with Padcev for treating adults with cisplatin-ineligible resectable muscle-invasive bladder cancer. This combination therapy is designed to improve outcomes for patients who have limited treatment options.
Read more →MRKNext-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
SureNano Science is developing GEP-44, a next-generation GLP-1 therapy aimed at improving metabolic health. The global market for GLP-1 therapies is rapidly expanding, with projections reaching $190 billion by 2035. GEP-44's unique triple agonist mechanism may enhance efficacy and tolerability compared to existing treatments. The company is also exploring innovative drug-delivery methods to improve patient adherence.
Read more →MRKMerck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026
Merck presented new long-term data and advancements in its oncology portfolio and pipeline research at the ASCO 2026 conference. The company highlighted its ongoing commitment to cancer research and development. Specific details regarding the data or advancements were not disclosed in the article.
Read more →MRKMerck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
Merck scientists have published a significant paper detailing a new method for the large-scale biocatalytic synthesis of the investigational oral PCSK9 inhibitor, Enlicitide Decanoate. This research could have implications for the treatment of cholesterol-related conditions. The publication highlights advancements in biocatalytic processes, although specific outcomes or applications were not discussed.
Read more →MRKMerck Completes Acquisition of Terns Pharmaceuticals, Inc.
Merck has successfully acquired Terns Pharmaceuticals, enhancing its focus on innovative treatments. The acquisition includes TERN-701, a promising therapy for chronic myeloid leukemia, which has received Breakthrough Therapy Designation from the FDA. This strategic move is expected to impact Merck's financials significantly, with a charge of approximately $5.8 billion anticipated.
Read more →MRKMerck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke
Merck has launched the Playing with Heart program in collaboration with nine professional baseball teams and former players. This initiative aims to educate adults about the significance of monitoring low-density lipoprotein cholesterol (LDL-C), often referred to as 'bad' cholesterol, and its association with heart attack and stroke risks. The program seeks to leverage the popularity of baseball to promote health awareness.
Read more →MRKMerck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Merck has announced the expiration of the Hart-Scott-Rodino waiting period for its acquisition of Terns Pharmaceuticals. This milestone allows Merck to proceed with its cash tender offer of $53.00 per share for Terns' outstanding stock. The completion of the acquisition is still subject to additional conditions, including shareholder participation.
Read more →MRKMerck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation
Merck has announced a significant partnership with Google Cloud to enhance its AI capabilities across various functions, including R&D and manufacturing. This collaboration, valued at up to $1 billion, aims to deploy advanced AI solutions to improve productivity and accelerate drug development. The partnership is expected to create a transformative agentic ecosystem that integrates technology with human expertise.
Read more →MRKFDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)
Merck has received FDA approval for IDVYNSO™, a new single-tablet regimen combining doravirine and islatravir for treating HIV-1 infection. This regimen is intended for adults who are already virologically suppressed on a stable antiretroviral regimen. The approval marks a significant advancement in HIV treatment options.
Read more →MRKFDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
The FDA has granted priority review for two supplemental applications for KEYTRUDA and KEYTRUDA QLEX, both in combination with Padcev, aimed at treating muscle-invasive bladder cancer (MIBC) patients eligible for cisplatin. The applications are supported by promising Phase 3 trial results indicating improved survival outcomes. If approved, these treatments could set new standards for perioperative care in MIBC.
Read more →MRKIfinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
Daiichi Sankyo and Merck's Biologics License Application for ifinatamab deruxtecan has been accepted for Priority Review by the FDA. This investigational drug targets adult patients with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. The application is supported by clinical trial results and aims to provide new treatment options for this difficult-to-treat cancer.
Read more →MRKMerck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
Merck has initiated a tender offer to acquire Terns Pharmaceuticals, Inc. This strategic move is part of Merck's ongoing efforts to expand its portfolio and enhance its capabilities in the biopharmaceutical sector. The acquisition reflects Merck's commitment to growth through strategic partnerships and investments.
Read more →MRKEuropean Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
The European Commission has approved KEYTRUDA (pembrolizumab) in combination with paclitaxel ± bevacizumab for adults with PD-L1 (CPS ≥1) platinum-resistant recurrent ovarian carcinoma. This approval provides a new treatment option for patients who have undergone one or two prior systemic treatments. The combination therapy aims to improve outcomes for this specific patient group.
Read more →MRKMerck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
Merck has announced the initiation of a pivotal Phase 2b/3 trial for MK-8748, a bispecific Tie2 agonist and VEGF inhibitor. This investigational treatment aims to address neovascular age-related macular degeneration. The trial's outcomes could significantly impact the treatment landscape for this condition.
Read more →MRKPositive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
Merck's WINREVAIR (sotatercept-csrk) demonstrated significant efficacy in the Phase 2 CADENCE trial, achieving its primary endpoint of reducing pulmonary vascular resistance in adults with combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction. The results support advancing to a registrational Phase 3 study, aiming to provide a treatment option for this underdiagnosed condition. Secondary endpoints also showed promising trends, reinforcing the drug's potential benefits.
Read more →MRKMerck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Merck has announced its acquisition of Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion. This acquisition aims to enhance Merck's hematology pipeline with TERN-701, a novel treatment for chronic myeloid leukemia currently in Phase 1/2 trials. The deal is expected to close in the second quarter of 2026, pending regulatory and shareholder approvals.
Read more →MRKMerck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
Merck will present new data on the long-term efficacy of its HPV vaccines, GARDASIL 9 and GARDASIL, at the EUROGIN International Multidisciplinary HPV Congress 2026. The data shows vaccine effectiveness lasting up to 18 years after administration. This presentation underscores the importance of HPV vaccination in preventing related cancers and diseases.
Read more →MRKMerck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
Merck announced new clinical data from its cardio-pulmonary pipeline to be presented at ACC.26. The data includes positive results from the Phase 3 CORALreef AddOn trial of enlicitide and the Phase 2 CADENCE trial of WINREVAIR. These findings underline Merck's dedication to addressing cardiovascular diseases, particularly hypercholesterolemia and CpcPH-HFpEF.
Read more →MRKWELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Merck and Eisai announced positive results from the Phase 3 LITESPARK-011 trial, showing that the combination of WELIREG (belzutifan) and LENVIMA (lenvatinib) reduced the risk of disease progression or death by 30% compared to cabozantinib in previously treated advanced renal cell carcinoma patients. The FDA has accepted two supplemental New Drug Applications for this combination therapy, with a target action date of October 4, 2026. The trial also reported a significant objective response rate of 52.6%.
Read more →MRKKEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
Merck announced positive results from the Phase 3 LITESPARK-022 trial, showing that the combination of KEYTRUDA and WELIREG significantly reduced the risk of disease recurrence or death in earlier-stage renal cell carcinoma patients. The U.S. FDA has accepted supplemental applications for this combination therapy for priority review. This trial marks a significant advancement in the treatment of renal cell carcinoma, potentially reshaping clinical practice.
Read more →MRKKEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Merck announced positive results from the Phase 3 KEYNOTE-B96 trial, showing that KEYTRUDA, in combination with paclitaxel with or without bevacizumab, significantly improves overall survival for patients with platinum-resistant recurrent ovarian cancer. The treatment reduced the risk of death by 18% compared to standard care. These findings will be presented at the ESGO 2026 Congress, highlighting Merck's commitment to addressing unmet needs in women's cancers.
Read more →MRKKEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
Merck announced that the combination of KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) significantly improves outcomes for patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. The therapy reduced event-free survival events by 47% and the risk of death by 35% compared to traditional neoadjuvant chemotherapy. These findings will be presented at the 2026 ASCO GU Cancers Symposium.
Read more →MRKFDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
Merck Animal Health has received FDA approval for NUMELVI™ (atinvicitinib tablets), the first second-generation JAK inhibitor for managing pruritus associated with allergic dermatitis in dogs aged six months and older. The product will be available in veterinary clinics by spring 2026. NUMELVI aims to enhance the health and comfort of dogs while offering convenience for veterinary practices.
Read more →MRKMerck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
Merck presented late-breaking data from three Phase 3 trials at CROI 2026, showcasing the efficacy and safety of the investigational two-drug regimen doravirine/islatravir (DOR/ISL) for HIV-1 treatment. DOR/ISL showed non-inferiority to the standard treatment BIC/FTC/TAF at Week 48 and maintained virologic suppression at Week 96. The findings suggest DOR/ISL could provide a new treatment option for adults living with HIV-1.
Read more →MRKMerck to Participate in the TD Cowen 46th Annual Health Care Conference
Merck announced that executives Caroline Litchfield and Dr. Dean Y. Li will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The event will be accessible via a live audio webcast for investors, analysts, and the public. Merck continues to focus on its mission to improve global health through innovative research.
Read more →MRKMerck Evolves Human Health Operating Structure to Support Portfolio Execution
Merck is restructuring its Human Health organization to enhance commercial execution across various therapeutic areas. This includes establishing an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. New appointments, including Jannie Oosthuizen and Brian Foard, aim to leverage their expertise for strategic growth. The company is also advancing a robust pipeline with numerous Phase 3 studies underway.
Read more →MRKMerck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
Merck and Mayo Clinic have announced a strategic collaboration to enhance drug discovery through artificial intelligence and advanced analytics. This partnership will integrate Mayo Clinic's clinical insights and genomic data with Merck's AI capabilities. The collaboration aims to focus on high-need therapeutic areas, potentially speeding up the development of effective therapies.
Read more →MRKMerck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
Merck announced the presentation of new data on genitourinary cancers at the 2026 ASCO GU Cancers Symposium. The studies will include findings on muscle invasive bladder cancer and renal cell carcinoma, showcasing Merck's commitment to improving patient outcomes. Key data will feature results from their cancer medicines, including KEYTRUDA, WELIREG, and LENVIMA, as well as an investigational ADC. This underscores Merck's leadership in the oncology field.
Read more →MRKKEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
Merck has received FDA approval for KEYTRUDA and KEYTRUDA QLEX, which are now indicated for adults with PD-L1+ platinum-resistant ovarian cancer. The approvals are based on the Phase 3 KEYNOTE-B96 trial, demonstrating significant improvements in progression-free and overall survival compared to placebo. This marks a notable advancement in treatment options for patients facing limited choices due to platinum resistance.
Read more →MRKMerck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants
Merck has received Health Canada approval for ENFLONSIA® (clesrovimab) to prevent respiratory syncytial virus (RSV) in newborns and infants. This monoclonal antibody offers protection during the RSV season and is supported by positive results from the CLEVER and SMART clinical trials. The approval enhances RSV prevention strategies for vulnerable infants across Canada.
Read more →MRKMerck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
Merck & Co., Inc. reported strong financial results for Q4 and full year 2025, with a notable increase in EPS and sales driven by oncology products like KEYTRUDA. The company also highlighted progress in its pipeline, including positive results from Phase 3 trials. However, challenges included a decline in gross margin and lower sales in the vaccines sector.
Read more →MRKMerck Announces Second-Quarter 2026 Dividend
Merck has announced a quarterly dividend of $0.85 per share for the second quarter of 2026. This dividend will be paid on April 7, 2026, to shareholders recorded by March 16, 2026. The announcement underscores Merck's commitment to returning value to its shareholders while continuing its mission in biopharmaceutical research and development.
Read more →MRKMerck to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Merck (MRK) announced that its CEO Robert M. Davis and EVP Dr. Dean Y. Li will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The event will be accessible via a live audio webcast, inviting investors, analysts, and the public to listen. This participation underscores Merck's ongoing commitment to advancing healthcare solutions.
Read more →MRKMerck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
Merck has announced a significant agreement with the U.S. government to enhance access to its medicines and reduce costs for American patients. This includes a direct-to-patient program offering key products at reduced prices. The company is also committing over $70 billion to U.S. manufacturing and innovation, aiming to address disparities in drug pricing. Enlicitide, a potential oral PCSK9 inhibitor, is expected to be part of this initiative pending FDA approval.
Read more →MRKMerck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
Merck announced plans to present first-in-human data for Alzheimer's candidates MK-2214 and MK-1167 at CTAD 2025. MK-2214 has received Fast Track Designation from the FDA, aimed at expediting its development for Alzheimer's treatment. The company emphasizes its commitment to addressing the challenges of Alzheimer's disease through innovative research.
Read more →MRKMerck to Participate in the Citi 2025 Global Healthcare Conference
Merck announced its participation in the Citi 2025 Global Healthcare Conference, scheduled for December 3, 2025. Chirfi Guindo and Dr. Eliav Barr will represent the company in a fireside chat. Investors and the public can access a live audio webcast of the event. Merck emphasizes its commitment to advancing health solutions.
Read more →MRKMerck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
Merck announced its participation in the 8th Annual Evercore ISI HealthCONx Conference, scheduled for December 2, 2025. Key executives, including Chirfi Guindo and Dr. Eliav Barr, will engage in a fireside chat. The event will be accessible to investors, analysts, and the public via a live audio webcast.
Read more →MRKMerck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
Merck will present new data at the ASH 2025 Annual Meeting, showcasing advancements in its hematology pipeline. The company is highlighting over 20 abstracts, including results from studies on MK-1045, bomedemstat, and nemtabrutinib. These presentations emphasize Merck's commitment to addressing significant unmet needs in hematologic malignancies.
Read more →Competitive Position
How MRK ranks across every disease it competes inCompetitive Position is a premium feature
See how MRK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial